Brendan Eckelman
Founder bei INHIBRX, INC.
Vermögen: 80 Mio $ am 30.04.2024
Aktive Positionen von Brendan Eckelman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INHIBRX, INC. | Founder | 01.04.2010 | - |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 01.04.2018 | 27.10.2021 |
Karriereverlauf von Brendan Eckelman
Ehemalige bekannte Positionen von Brendan Eckelman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Chief Operating Officer | 01.01.2010 | - |
Founder | 01.01.2010 | - |
Ausbildung von Brendan Eckelman
University of California San Diego | Graduate Degree |
UC San Diego School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Founder | 2 |
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INHIBRX, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
- Börse
- Insiders
- Brendan Eckelman
- Erfahrung